Compare Gilead Sciences, Inc. (GILD) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Orion Office REIT Inc — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while Orion Office REIT Inc trades at $2.69 (market cap $151.17M). The key difference: Gilead Sciences, Inc. is far larger — about 1081.6× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3.01%). Which is the better fit depends on your goals.
| GILD | ONL | |
|---|---|---|
Market Cap | $163.51B | $151.17M |
Sector | Health | Real Estate |
52-Week High | $155.80 | $3.04 |
52-Week Low | $108.22 | $1.93 |
Enterprise Value | $178.05B | $634.82M |
Dividend Yield | 2.49% | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
ONL trades at $2.695, up 1.32% with a bearish technical signal. The REIT shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, with a -98.36% net margin. However, positive cash flow from operations and a strategic review with Wells Fargo and JPMorgan provide some optimism. Analyst sentiment is split evenly between Buy and Hold recommendations.
The outlook is challenged by fundamental weakness but supported by balance sheet management efforts. Investment opportunity lies in the potential outcome of the strategic review and portfolio repositioning. Key risks include continued revenue erosion, high debt levels, and negative funds from distribution amid significant capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
